Comparative effects of therapies with donor-derived immunosuppressive MR-DCs and DST in mice. (A) Survival of BALB/c cardiac allografts in recipient B6 mice treated intravenously (or not, control), 7 days before transplantation with BALB/c MR-DCs alive or apoptotic. (B) Survival of B6 cardiac transplantations in recipient BALB/c mice untreated or injected intravenously 7 days before transplantation with MR-DCs generated from wild-type or MHC I/II^{double KO} B6 mice. (C) Comparison of survival of BALB/c cardiac allografts in recipient B6 mice pretreated (intravenously) 7 days before transplantation with viable BALB/c MR-DCs, or with BALB/c splenocytes alive or apoptotic.